These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27237059)

  • 1. Dynamic contrast enhanced MRI monitoring of primary proton and carbon ion irradiation of prostate cancer using a novel hypofractionated raster scan technique.
    Bonekamp D; Wolf MB; Edler C; Katayama S; Schlemmer HP; Herfarth K; Röthke M
    Radiother Oncol; 2016 Aug; 120(2):313-9. PubMed ID: 27237059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffusion-weighted MRI treatment monitoring of primary hypofractionated proton and carbon ion prostate cancer irradiation using raster scan technique.
    Wolf MB; Edler C; Tichy D; Röthke MC; Schlemmer HP; Herfarth K; Bonekamp D
    J Magn Reson Imaging; 2017 Sep; 46(3):850-860. PubMed ID: 28152251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring radiotherapy induced tissue changes in localized prostate cancer by multi-parametric magnetic resonance imaging (MP-MRI).
    Wu X; Reinikainen P; Kapanen M; Vierikko T; Ryymin P; Kellokumpu-Lehtinen PL
    Diagn Interv Imaging; 2019 Nov; 100(11):699-708. PubMed ID: 31257114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DCE-MRI of the prostate using shutter-speed vs. Tofts model for tumor characterization and assessment of aggressiveness.
    Hectors SJ; Besa C; Wagner M; Jajamovich GH; Haines GK; Lewis S; Tewari A; Rastinehad A; Huang W; Taouli B
    J Magn Reson Imaging; 2017 Sep; 46(3):837-849. PubMed ID: 28092414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of arterial spin labeling perfusion MRI and DCE-MRI in human prostate cancer.
    Cai W; Li F; Wang J; Du H; Wang X; Zhang J; Fang J; Jiang X
    NMR Biomed; 2014 Jul; 27(7):817-25. PubMed ID: 24809332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimized Fast Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate: Effect of Sampling Duration on Pharmacokinetic Parameters.
    Othman AE; Falkner F; Martirosian P; Schraml C; Schwentner C; Nickel D; Nikolaou K; Notohamiprodjo M
    Invest Radiol; 2016 Feb; 51(2):106-12. PubMed ID: 26447494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ion Prostate Irradiation (IPI) - a pilot study to establish the safety and feasibility of primary hypofractionated irradiation of the prostate with protons and carbon ions in a raster scan technique.
    Habl G; Hatiboglu G; Edler L; Uhl M; Krause S; Roethke M; Schlemmer HP; Hadaschik B; Debus J; Herfarth K
    BMC Cancer; 2014 Mar; 14():202. PubMed ID: 24641841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
    Ocak I; Bernardo M; Metzger G; Barrett T; Pinto P; Albert PS; Choyke PL
    AJR Am J Roentgenol; 2007 Oct; 189(4):849. PubMed ID: 17885055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Single Dose Photons and Carbon Ions on Perfusion and Vascular Permeability: A Dynamic Contrast-Enhanced MRI Pilot Study in the Anaplastic Rat Prostate Tumor R3327-AT1.
    Bendinger AL; Seyler L; Saager M; Debus C; Peschke P; Komljenovic D; Debus J; Peter J; Floca RO; Karger CP; Glowa C
    Radiat Res; 2020 Jan; 193(1):34-45. PubMed ID: 31697210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeatability and correlations of dynamic contrast enhanced and T2* MRI in patients with advanced pancreatic ductal adenocarcinoma.
    Klaassen R; Gurney-Champion OJ; Wilmink JW; Besselink MG; Engelbrecht MRW; Stoker J; Nederveen AJ; van Laarhoven HWM
    Magn Reson Imaging; 2018 Jul; 50():1-9. PubMed ID: 29476781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute Toxicity and Quality of Life in Patients With Prostate Cancer Treated With Protons or Carbon Ions in a Prospective Randomized Phase II Study--The IPI Trial.
    Habl G; Uhl M; Katayama S; Kessel KA; Hatiboglu G; Hadaschik B; Edler L; Tichy D; Ellerbrock M; Haberer T; Wolf MB; Schlemmer HP; Debus J; Herfarth K
    Int J Radiat Oncol Biol Phys; 2016 May; 95(1):435-443. PubMed ID: 27084659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of Fitting Model and Arterial Input Function for Repeatability in Dynamic Contrast-Enhanced Prostate MRI.
    Peled S; Vangel M; Kikinis R; Tempany CM; Fennessy FM; Fedorov A
    Acad Radiol; 2019 Sep; 26(9):e241-e251. PubMed ID: 30467073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
    Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI.
    van Lin EN; Fütterer JJ; Heijmink SW; van der Vight LP; Hoffmann AL; van Kollenburg P; Huisman HJ; Scheenen TW; Witjes JA; Leer JW; Barentsz JO; Visser AG
    Int J Radiat Oncol Biol Phys; 2006 May; 65(1):291-303. PubMed ID: 16618584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of contrast agent injection duration on dynamic contrast-enhanced MRI quantification in prostate cancer.
    Klawer EME; van Houdt PJ; Pos FJ; Heijmink SWTPJ; van Osch MJP; van der Heide UA
    NMR Biomed; 2018 Sep; 31(9):e3946. PubMed ID: 29974981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Temporal Resolution on Diagnostic Performance of Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate.
    Othman AE; Falkner F; Weiss J; Kruck S; Grimm R; Martirosian P; Nikolaou K; Notohamiprodjo M
    Invest Radiol; 2016 May; 51(5):290-6. PubMed ID: 26619282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic gadolinium-enhanced perfusion MRI of prostate cancer: assessment of response to hypofractionated robotic stereotactic body radiation therapy.
    Low RN; Fuller DB; Muradyan N
    AJR Am J Roentgenol; 2011 Oct; 197(4):907-15. PubMed ID: 21940578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of MRI-only treatment planning for proton therapy in brain and prostate cancers: Dose calculation accuracy in substitute CT images.
    Koivula L; Wee L; Korhonen J
    Med Phys; 2016 Aug; 43(8):4634. PubMed ID: 27487880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of different population-averaged arterial-input-functions in dynamic contrast-enhanced MRI of the prostate: Effects on pharmacokinetic parameters and their diagnostic performance.
    Othman AE; Falkner F; Kessler DE; Martirosian P; Weiss J; Kruck S; Kaufmann S; Grimm R; Kramer U; Nikolaou K; Notohamiprodjo M
    Magn Reson Imaging; 2016 May; 34(4):496-501. PubMed ID: 26708031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer detection on dynamic contrast-enhanced MRI: computer-aided diagnosis versus single perfusion parameter maps.
    Sung YS; Kwon HJ; Park BW; Cho G; Lee CK; Cho KS; Kim JK
    AJR Am J Roentgenol; 2011 Nov; 197(5):1122-9. PubMed ID: 22021504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.